Medical Countermeasures - Medical
Abstract
To further develop an expedited medical countermeasure capability, emerging technologies will be integrated to address the safety considerations in the risk/benefit package required for Emergency Use Authorization (EUA) issuance to counter naturally emerging or engineered biological warfare threats. These technologies will also be focused on new safety standards to reduce the time, risk, and cost associated with licensing a new therapeutic which might be considered under an EUA.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2012
- Source ID
- b60dc2585e198228f9128f7e3a79c950